CELLINK AB (publ) (“CELLINK” or the “Company”) (CELLINK is listed on Nasdaq First North Growth Market under CLNK B) announced on April 3, 2020, that Nasdaq Stockholm’s listing committee had approved that the Company’s shares are admitted to trading on Nasdaq Stockholm’s Main Market, following the fulfilment of customary conditions. Today, on April 15, 2020, the prospectus that has been prepared by the Company in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority (“SFSA”) and is now available on CELLINK’s website, www.cellink.com, and on SFSA’s website, www.fi.se.
CELLINK’s first day of trading on Nasdaq Stockholm’s Main Market is planned to be April 20, 2020. The last day of trading on Nasdaq First North Growth Market is planned to be April 17, 2020.
The information was sent for publication, through the agency of the contact persons set out above, on April 15, 2020, at 8:35 CEST.
CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK B. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected]